MicroPort® Coronary Stents Achieve Dual Milestone of Over 10 Million Units Shipped and Implanted Globally

China, Shanghai — Recently, Shanghai MicroPort Medical (Group) Co., Ltd. (referred to as "MicroPort"), a subsidiary of MicroPort Scientific Corporation (00853.HK),^®MicroPort announced that, as of the end of September 2025, the cumulative global shipments and implantations of its full series of coronary stent systems have both surpassed the milestone of "10 million units." Among them, overseas sales account for approximately 20% and are showing a rapid growth trend.

By continuously cultivating the local market and expanding global business, MicroPort has achieved significant milestones as of now.^®Coronary stents have been deployed in over 4,000 hospitals across 34 provincial administrative regions in China. Among them, through the "Feiyan Project," interventional treatment technology has reached more than 1,300 county-level hospitals. Since its market launch in 2004, it has consistently ranked first in market share nationwide, cumulatively serving over 6 million patients. Currently, its overall market share in China is 43%.

On the international stage, MicroPort^®The footprint of coronary interventions has spread to over 3,000 hospitals across nearly 90 countries and regions. In recent years, MicroPort^®Key breakthroughs and impressive performance have been achieved in multiple strategic and emerging markets, including Europe, Asia, South America, and North America: the compound annual growth rate of sales from 2021 to 2024 reached 35%, with the sales volume of the DES product portfolio increasing by approximately 300%. As overseas operations continue to expand, their contribution to coronary stent sales has also been increasing year by year, growing from 15% in 2021 to nearly 30% in 2024. The expected shipment volume for 2025 alone is close to 400,000 units.

“The growth of these data is attributed to MicroPort.^®Strong brand influence and solid product performance are also due to the 'self-owned global promotion platform + agent channel'.’The breakthrough in geographical breadth brought by the hybrid strategy." MicroPort^®Ms. Liang Min, Head of Overseas Commercial, emphasized, "MicroPort^®Will continue to expand overseas core markets, while actively promoting product iteration and the implementation of new technologies in overseas markets."Currently, Firehawk^®Completely Iterated to Firehawk in the High-end Market^® Liberty, the intravascular shock wave catheter system, OCT optical coherence tomography system, bioresorbable scaffolds, and other new products are also accelerating their rollout.

As MicroPort^®The earliest product series under the medical sector, the coronary product family, started in 1998 when the company was founded. In 2004, the company launched China's first drug-eluting stent, Firebird™, which gained high clinical recognition in the same year it was marketed, capturing 40% of the Chinese market share. From 2009 to 2014, the iterative product Firebird2...^®/Firebird™ to the world's first clinically used Targeted Drug-Eluting Stent Firehawk^®/FireHawk^®, MicroPort^®Spent 5 years achieving a transformation from a technology follower to a technology leader in the coronary stent field, and will continue to launch the new generation of bioresorbable scaffold Firesorb in 2024.^®/Scarlet Ibis^®。

Today's MicroPort^®The Coronary Product Family, Including Five Stent Systems That Meet Global Clinical Needs and Patient Personalization: Firesorb^®/Fire Ibis^®Bioabsorbable支架、Firehawk^®/FireHawk^®Drug-Eluting Stent, FireCondor^®/Fire God Eagle^®Drug-Eluting Stent (Overseas Product Registration Name: Firehawk)^® Liberty ）、Firebird2^®/Firebird™ Drug-Eluting Stent and Firebird Pro+^®/Firebird Pro+™ Drug-Eluting Stent, while also gradually building a comprehensive solution for the treatment of coronary artery disease that includes “passive devices + active equipment + imaging detection products”: China's first coronary rotational atherectomy system, China’s first batch of OCT optical coherence tomography imaging equipment, and intravascular lithotripsy catheter systems have successively been launched. The coronary intravascular piezoelectric guidewire system is expected to be approved for marketing this year, and other products under research such as the coronary sinus balloon counterpulsation system will also quickly advance into clinical use. With persistent investment in innovation, MicroPort continues to iterate and launch innovative products to protect coronary heart disease patients worldwide.

On August 31 this year, the top journal *The New England Journal of Medicine* and the European Society of Cardiology Congress simultaneously released the results of the TARGET-FIRST study: For low-risk acute myocardial infarction (AMI) patients, Firehawk^®/Firehawk^®Stents can shorten the dual antiplatelet therapy (DAPT) course from 12 months to 1 month, which not only does not increase the risk of ischemia but also reduces the risk of bleeding complications by 54%. This exciting research finding has drawn significant attention from authoritative medical organizations such as the American College of Cardiology and the American Heart Association. In fact, as early as 2018, studies surrounding the Firehawk...^®/FireHawk^®Another clinical study, TARGET AC, was featured in the top journal *The Lancet* for addressing the challenge of "late stent thrombosis." These research achievements not only established a comprehensive foundation for Firehawk.^®/FireHawk^®The evidence-based medicine system has also enabled Chinese medical device companies to gain widespread recognition and respect in the international market and academic field.

As of now, the TARGET series of "Firehawk" has been carried out in more than 200 medical centers worldwide, with over 17,500 patients enrolled cumulatively; while "Firebird" has been on the market for a short time, and its FUTURE series of three studies have already completed 3 to 5 years of follow-up for over 1,400 patients.

MicroPort^®Dr. Yue Bin, President of Coronary Division, said: "10 million stents, each one carries the patient's longing for life, the doctor's dedication to professionalism, and MicroPort^®Coronary artery's commitment and responsibility to society. This will be a new starting point. The company will not only continue to promote the iterative innovation of cardiac stents but also aim for more 'tens of millions' level targets across its full range of product lines, including passive devices, active equipment, and imaging detection products. At the same time, it will make advancements in intelligent surgery, as well as telemedicine and home healthcare, striving to become a global leader in technological innovation and commercialization capabilities within the coronary field.

MicroPort^®Chief Marketing Officer of Greater China, MicroPort^®Mr. Jiang Lei, Chairman of MicroPort, stated: "This milestone marks a solid leap forward in China's medical device independent innovation from 'catching up' to 'leading.' Today, this innovative momentum has extended to business areas such as surgical robots, heart valves, electrophysiology, and rhythm management."^®"We will continue to work towards more 'quantum' milestones. In the future, the group will join hands with global partners to promote efficient market expansion and broaden commercial reach in each sector through a multi-point linked, highly collaborative network, faithfully practicing the inspiring mission of 'providing life-extending and life-transforming universal solutions that are truly good, kind, and beautiful for hundreds of millions of patients.'"

*Disclaimer: The descriptions of clinical effects and related data in this article are all derived from publicly available clinical research results or official corporate disclosures, and do not constitute any form of medical advice or product promotion. For any medical diagnosis issues, please be sure to consult professional healthcare personnel.